- Endo Tools Therapeutics has raised €20 million ($23 million) in Series C funding to accelerate commercialization of its FDA-cleared endomina® EZFuse system and expand the adoption of minimally invasive endoscopic obesity procedures. The investment will support growth across the U.S., Europe, and the Middle East while generating clinical evidence for a future U.S. weight-loss indication.
- The company is positioning its endoscopic suturing platform as an alternative or complement to GLP-1 therapy for patients with Class I and II obesity. The newly cleared EZFuse system simplifies endoscopic suturing with a single-motion mechanism that reduces procedure time, physician fatigue, and workflow complexity, potentially enabling hospitals and ambulatory surgery centers to perform more procedures efficiently. The funding underscores continued investor confidence in incisionless therapeutic endoscopy and the growing market for minimally invasive obesity treatments.
Keep Reading
Add A Comment